Nexvet Biopharma plc Ordinary Shares
NVET
NVET was delisted on the 28th of July, 2017.
20 hedge funds and large institutions have $19.7M invested in Nexvet Biopharma plc Ordinary Shares in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 19 → 20 (+1)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
8% less capital invested
Capital invested by funds: $21.5M → $19.7M (-$1.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$2.85M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$654K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$175K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$105K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$51.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.42M |
| 2 |
Jennison Associates
New York
|
-$954K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$218K |
| 4 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
-$111K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$87K |
NVET Hedge Fund Activity: Q4 2015 in Review
20 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q4 2015, worth a combined $19.7M — down 8.2% from $21.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NVET positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $2.85M. The largest seller was Wellington Management Group, cutting an estimated $3.42M.
- 20 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q4 2015, up from 19 in Q3 2015.
- Funds reported $19.7M of Nexvet Biopharma plc Ordinary Shares stock for Q4 2015, down 8.2% quarter-over-quarter.
- 5 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q4 2015 and 4 closed out, a net change of +1 holder.
- The largest Nexvet Biopharma plc Ordinary Shares buyer in Q4 2015 was Broadfin Capital, an estimated $2.85M added.
- The largest Nexvet Biopharma plc Ordinary Shares seller in Q4 2015 was Wellington Management Group, an estimated $3.42M sold.
Based on aggregated 13F filings for Q4 2015.